Streetbeat News

Price Targets

VKTX

Truist Securities analyst Joon Lee has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:55 pm

HBAN

Morgan Stanley analyst Ken Zerbe has maintained an Overweight rating on Huntington Bancshares (NASDAQ:HBAN) and increased the price target from $12 to $13.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:54 pm

GS

Morgan Stanley analyst Betsy Graseck has maintained an Equal-Weight rating on Goldman Sachs Group (NYSE:GS) and increased the price target from $329 to $333.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:53 pm

EW

Morgan Stanley analyst Patrick Wood has maintained an Overweight rating on Edwards Lifesciences (NYSE:EW) but has reduced the price target from $102 to $80.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:51 pm

PFE

Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Pfizer (NYSE:PFE) and maintained a $42 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:49 pm

DXCM

Morgan Stanley analyst Patrick Wood has maintained an Equal-Weight rating on DexCom (NASDAQ:DXCM) and increased the price target from $101 to $122.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:49 pm

NOG

Truist Securities analyst Neal Dingmann has reiterated a Buy rating on Northern Oil & Gas (NYSE:NOG) and maintained a $55 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:47 pm

CBSH

Morgan Stanley analyst Manan Gosalia has maintained an Equal-Weight rating on Commerce Bancshares (NASDAQ:CBSH) and reduced the price target from $46.67 to $46.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:45 pm

RCL

Truist Securities analyst Patrick Scholes has reiterated a Buy rating on Royal Caribbean Group (RCL) and maintained a price target of $134.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:45 pm

PRAX

Truist Securities analyst Joon Lee has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a $150 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 3:43 pm